The stock of Zogenix, Inc. (NASDAQ:ZGNX) is a huge mover today! About 110,193 shares traded hands. Zogenix, Inc. (NASDAQ:ZGNX) has declined 14.17% since April 5, 2016 and is downtrending. It has underperformed by 16.12% the S&P500.
The move comes after 5 months positive chart setup for the $237.50M company. It was reported on Nov, 8 by Barchart.com. We have $19.62 PT which if reached, will make NASDAQ:ZGNX worth $263.63M more.
Analysts await Zogenix, Inc. (NASDAQ:ZGNX) to report earnings on November, 14. They expect $-0.95 earnings per share, down 43.94% or $0.29 from last year’s $-0.66 per share. After $-0.78 actual earnings per share reported by Zogenix, Inc. for the previous quarter, Wall Street now forecasts 21.79% negative EPS growth.
Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage
Out of 2 analysts covering Zogenix (NASDAQ:ZGNX), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zogenix has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Brean Capital maintained the stock with “Buy” rating in Thursday, September 17 report. Zacks upgraded the shares of ZGNX in a report on Saturday, August 15 to “Hold” rating. The stock of Zogenix, Inc. (NASDAQ:ZGNX) has “Sell” rating given on Thursday, August 6 by Zacks. On Friday, August 14 the stock rating was maintained by Brean Capital with “Buy”. The rating was maintained by Leerink Swann with “Outperform” on Tuesday, August 11.
According to Zacks Investment Research, “Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, SumavelÂ™ DoseProÂ™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA.”
More news for Zogenix, Inc. (NASDAQ:ZGNX) were recently published by: Fool.com, which released: “Zogenix, Inc. Shares Galloped 15% Higher in February — Here’s Why” on March 10, 2016. Fool.com‘s article titled: “Zogenix, Inc Gained 29% in 2015 — Here’s Why” and published on January 14, 2016 is yet another important article.
ZGNX Company Profile
Zogenix, Inc., incorporated on May 11, 2006, is a pharmaceutical firm engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine. The Firm is also engaged in the development of Relday. It is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, under an Asset Purchase Agreement with Endo Ventures Bermuda Limited and Endo Ventures Limited (collectively, Endo). The Firm sells Sumavel DosePro to Endo.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.